Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
JCO Oncol Pract. 2023 May;19(5):265-275. doi: 10.1200/OP.22.00396. Epub 2023 Feb 28.
Despite significant progress and improving outcomes in the management of plasma cell disorders, AL amyloidosis remains diagnostically and therapeutically challenging for clinicians across practice settings. There is, however, a reason for optimism with the advent of new combination therapy approaches and novel targets offering the promise of improvement in end organ function, survival, and quality of life. This review offers a clinically applicable overview of an approach to diagnosis, risk stratification, and clinical management of AL amyloidosis in an era of rapid therapeutic innovation.
尽管在浆细胞疾病的治疗方面取得了重大进展和改善,但 AL 淀粉样变性在不同临床环境下的临床医生的诊断和治疗方面仍然具有挑战性。然而,随着新的联合治疗方法和新靶点的出现,有望改善终末器官功能、生存和生活质量,为人们带来了乐观的理由。本文在治疗创新快速发展的时代,对 AL 淀粉样变性的诊断、风险分层和临床管理方法进行了临床适用性概述。